Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly’s Donanemab Slows Cognitive Decline; FDA Filing Imminent

Full Approval Sought After Accelerated Nod Denied Previously

May 03 2023

• By Mandy Jackson

Alzheimer's disease on MRI — Donanemab slowed cognitive decline in Phase III • Source: Shutterstock

Related Content

A Banner Moment For Alzheimer's Positions Eisai/Biogen At The Head Of The Pack

Sep 28 2022

Lilly Focuses On ‘Traditional’ Approval For Donanemab, Increased Mounjaro Production

Feb 02 2023

Eisai/Biogen’s Leqembi Will Launch Below Aduhelm At $26,500 Per Year

Jan 06 2023

US FDA Rejects Lilly’s Bid For Donanemab Accelerated Approval In Early Alzheimer’s

Jan 20 2023

Lilly Sees Positive Results With Next-Gen Alzheimer’s Drug Donanemab

Jan 12 2021

Eisai/Biogen’s Lecanemab Effective Across Endpoints, But Will Safety Limit Use?

Nov 30 2022

How Biogen’s Aduhelm Bet Became A Commercial Bust

Jun 06 2022

Related Companies

Eli Lilly and Company

Eisai Co., Ltd.

Biogen, Inc.

Additional Topics

Clinical Trials Strategy Drug Safety Research & Development Neurology BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.